Research Progress on Resistance Mechanisms and Overcoming Strategies to Third-generation EGFR-TKIs in Advanced Non-small Cell Lung Cancer

Targeted therapy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) has been the standard modality as the first-line treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC). The first- and second-generation EGFR-TKIs have shown significant efficacy in NSCLC patie...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: HE Jingyi, WU Fang, HU Chunhong
Format: Artigo
Langue:Chinês
Publié: Magazine House of Cancer Research on Prevention and Treatment 2019-10-01
Collection:Zhongliu Fangzhi Yanjiu
Sujets:
egfr
the third-generation egfr-tkis
osimertinib
non-small cell lung cancer
resistance mechanisms
Accès en ligne:http://html.rhhz.net/ZLFZYJ/html/8578.2019.19.0169.htm
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires